Supplementary file 1_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a sy... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”

Supplementary file 2_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a sy... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”

Data Sheet 1_Efficacy and safety of the commercial Chinese polyherbal preparation Liu Shen Wan as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a systematic... by Yajing Li (1394572)

“…Meta-analysis demonstrated that LSW plus conventional treatment significantly outperformed conventional treatment alone in shortening vesicle cessation time [MD = −1.44, 95% CI (−1.66, −0.93), p < 0.00001, I² = 70%], accelerating scab formation (MD = −1.72, 95% CI (−2.09, −1.35), p < 0.00001, I² = 38%), reducing scab shedding time (MD = −2.22, 95% CI (−3.64, −0.80), p = 0.002, I² = 36%), decreasing time to pain resolution (MD = −2.46, 95% CI (−3.52, −1.39), p < 0.00001, I² = 0%), and shortening pain persistence duration (MD = −1.97, 95% CI (−2.49, −1.46), p < 0.00001, I² = 86%). …”

Data_Sheet_1_Formulation of Bio-Based Washing Agent and Its Application for Removal of Petroleum Hydrocarbons From Drill Cuttings Before Bioremediation.docx by Noulkamol Arpornpong (9227081)

“…After 49-day incubation, the TPHs were reduced to 0.9% by both physical and biological mechanisms, while the TPHs in the unamended samples remained unaffected. …”

Table_1_Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation.docx by Quirino Lai (8637660)

“…The risk factors for 10-year OS were macrovascular invasion (OR = 2.71; P = 0.001), poor grading (OR = 1.56; P = 0.001), HCV status (OR = 1.39; P = 0.001), diameter of the target lesion (OR = 1.09; P = 0.001), AFP slope (OR = 1.63; P = 0.006), and patient age (OR = 0.99; P = 0.01). …”

Image3_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.JPEG by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

Table1_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.XLSX by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

Image7_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.JPEG by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

Image5_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.JPEG by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

Image4_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.JPEG by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

DataSheet1_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.docx by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

Image6_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.JPEG by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

Image2_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.JPEG by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

Image1_Facial mask acute effects on affective/psychological and exercise performance responses during exercise: A meta-analytical review.JPEG by Marcelo Henrique Glänzel (10403520)

“…Mask-wearing during exercise lead to increased overall discomfort (SMD: 0.87; 95% CI 0.25–1.5; p = 0.01; I² = 0%), dyspnea (SMD: 0.40; 95% CI 0.09–0.71; p = 0.01; I² = 68%), and perceived exertion (SMD: 0.38; 95% CI 0.18–0.58; p < 0.001; I² = 46%); decreases on the TTE (SMD: −0.29; 95% CI −0.10 to −0.48; p < 0.001; I² = 0%); without effects on PO_MAX and walking/running distance traveled (p > 0.05).…”

DataSheet1_Pharmacogenetic association of the NR1H3 promoter variant with antihypertensive response among patients with hypertension: A longitudinal study.docx by Yu Chen (29959)

“…Patients carrying rs11039149AG genotype showed a significant increase of systolic blood pressure (SBP) at follow-up compared with AA carriers, and the difference of ΔSBP between AG and AA carriers was 5.94 mm Hg (95%CI: 2.09–9.78, p = 0.002). In 1,184 patients with CCBs therapy, SBP levels decreased in AA carriers, but increased in AG carriers, the difference of ΔSBP between AG and AA carriers was 8.04 mm Hg (95%CI: 3.28–12.81, p = 0.001). …”

<i>EGFR</i> mutation testing, treatment and survival in stage I–III non-small cell lung cancer: CancerLinQ Discovery database retrospective analysis by Bharathi Muthusamy (19200092)

Treatment with a fecal microbiota transplant following spinal cord injury reduced anxiety-like behaviour. by Emma K. A. Schmidt (8307642)

“…Although not significant, SCI rats also displayed a reduced percentage of open arm entries compared to sham (p = 0.1352) and SCI-FMT rats (p = 0.0909). <b>(E)</b> 4 weeks after injury, rats were tested in the light-dark box with increased time and reduced latency to enter the light component indicating decreased anxiety-like behaviour. …”

Enhanced Cuprophilic Interactions in Crystalline Catalysts Facilitate the Highly Selective Electroreduction of CO₂ to CH₄ by Lei Zhang (38117)

“…Consequently, <b>NNU-33­(H)</b> with enhanced cuprophilic interactions shows an outstanding product (CH₄) selectivity of 82% at −0.9 V (vs reversible hydrogen electrode, <i>j</i> = 391 mA cm^–2), which represents the best crystalline catalyst for electrocatalytic CO₂-to-CH₄ conversion to date. …”

Supplementary Material for: Cilostazol for Aneurysmal Subarachnoid Hemorrhage: An Updated Systematic Review and Meta-Analysis by Liu J. (3215370)

“…In 3 OSs which reported different doses of cilostazol (300 mg/day vs. 100–200 mg/day) for aSAH, the 300-mg/day cilostazol groups showed decreased delayed cerebral infarction (RR 0.27, 95% CI 0.09–0.81, <i>p</i> = 0.02) but no significant difference in shunt-dependent hydrocephalus (RR 0.92, 95% CI 0.33–2.60, <i>p</i> = 0.88) or functional outcomes (RR 1.14, 95% CI 0.74–1.75, <i>p</i> = 0.56) compared with the 100–200 mg/day cilostazol groups. …”

Assessing the Causal Role of Walking Pace and Hand Grip Strength with Chronic Obstructive Pulmonary Disease Hospital: A Mendelian Randomization Study by Lu Wang (45927)

“…It also reveals a potential association between gait speed and the likelihood of developing early-onset COPD (OR = 0.189, 95% CI 0.09 to 0.39; <i>p</i> = 8.89 × 10-6) as well as late-onset COPD (OR = 0.44, 95% CI 0.25 to 0.76; <i>p</i> = 0.0036). …”